Activity Overview
Multiple sclerosis (MS) affects nearly 400 000 people in the United States and over 2.5 million people worldwide. Its presentation and course are highly variable and often unpredictable, and the diagnostic criteria for MS continue to evolve, reflecting ongoing advancements in neuroimaging and neuroimmunology. The effects of MS can be devastating, and it remains the most common disabling neurologic condition in young adults.

Managed care pharmacists play a key role in the management of patients with MS, educating patients and fellow clinicians, and monitoring therapeutic efficacy while screening for potential adverse effects. In addition, the managed care pharmacist must make difficult and often complex decisions regarding the effects of MS and its treatment on health systems, managed care plans, and large patient groups.

This educational activity will provide managed care pharmacists with a thorough and timely update, including practical strategies for translating the latest medical and scientific developments into the best possible patient outcomes and unique perspectives in the managed care setting.

Goal
To provide pharmacists working in managed care, Veterans Affairs, and Department of Defense settings with clinical updates to improve neuroprotection, evaluate how to utilize imaging modalities to observe the clinical and immunological effects of disease-modifying therapies on the pathology of multiple sclerosis, and design and implement strategies to improve patient adherence to therapy.

Intended Audience
This activity is designed for managed care, Veterans Affairs, and Department of Defense pharmacists. No prerequisites required.

Learning Objectives
Upon the conclusion of this activity, the participant should be able to:

  • Describe the pathophysiology and the biology of demyelination, axonal degeneration, and neuronal cell death in multiple sclerosis (MS).
  • Explain the potential role current and future immunomodulatory therapies have in promoting neuroprotection and neuroregeneration.
  • Evaluate the long-term safety and efficacy of available immune-modulating MS agents and methods used to monitor the effectiveness of MS therapies.
  • Identify issues regarding the management of MS in managed care.

The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CE activity.

The estimated time to complete this educational activity: 1.5 hours.

Release date: September 15, 2009. Expiration date: September 15, 2011.

Accreditation Statement
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

Credit Designation Statement
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based educational activity will provide 1.5 contact hours credit (0.15 CEUs). Successful completion includes participating in the activity, completing a self-assessment instrument with a score of at least 70%, and completing an evaluation instrument. If you score less than 70% on the self-assessment instrument, you will be allowed to complete the examination one more time. ACPE Program #064-000-09-205-L01-P.

Faculty
Jacquelyn Bainbridge, PharmD, FCCP (Chair)
Associate Professor
Department of Clinical Pharmacy/Department of Neurology
University of Colorado Denver
Aurora, CO

Jeffrey L. Bennett, MD, PhD
Associate Professor
Departments of Neurology and Ophthalmology
University of Colorado Denver School of Medicine
Aurora, CO

Melody Ryan, PharmD, MPH, BCPS, CGP
Associate Professor
Department of Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Department of Neurology
University of Kentucky College of Medicine
Lexington, KY

Ellen Whipple Guthrie, PharmD
Clinical Assistant Professor
University of Georgia College of Pharmacy
Athens, GA
Pediatric Pharmacist
Children’s Healthcare of Atlanta at Egleston
Atlanta, GA

Sheldon J. Rich, RPh, PhD
President, SJR Associates, LLC
Palm Beach Gardens, FL
Clinical Assistant Professor, University of Michigan
Ann Arbor, MI
Adjunct Assistant Professor, Wayne State University
Detroit, MI

Policy on Faculty and Provider Disclosure
It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the presentations.

Supported by an educational grant from Teva Neuroscience.
Step 1. Webcast

 
Step 2. Post-test

     
Home | Contact Us | View Account | Need Help? | Subscription